Dexcom, Inc. 8-K/A Report: Key Amendments and Updates for Investors

Based on the provided section of the financial report, here are the key insights extracted:

1. Entity Information:

• Company Name: Dexcom, Inc.
• State of Incorporation: Delaware (DE)
• CIK: 0001093557
• Address: 6340 Sequence Drive, San Diego, CA 92121
• Phone Number: 858-200-0200

2. Filing Details:

• Filing Type: 8-K/A (Amendment to a current report)
• Filing Date: March 6, 2025
• SEC File Number: 000-51222
• Securities Registration Number: 33-0857544

3. Stock Information:

• Common Stock Par Value: $0.001 per share
• Ticker Symbol: DXCM
• Exchange: NASDAQ

4. Reporting Period:

• Report Date: March 6, 2025 (the same as the filing date)

Summary Insights:

• This report is an amendment (8-K/A) from Dexcom, Inc., indicating that the company is making updates or corrections to previously filed information as of March 6, 2025.
• The company operates in the healthcare technology sector, specifically focusing on diabetes management solutions, which is implied by its name.
• The report is filed with the SEC, suggesting regulatory compliance and the need to provide timely updates to shareholders and the market.
• Dexcom is publicly traded on NASDAQ under the ticker DXCM, indicating its status as a publicly held corporation.

This information may be important for investors and analysts tracking the company’s performance or any significant events that could affect its stock price or operations.